KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Amortization - Intangibles (2017 - 2025)

Sarepta Therapeutics has reported Amortization - Intangibles over the past 9 years, most recently at $677000.0 for Q4 2025.

  • Quarterly results put Amortization - Intangibles at $677000.0 for Q4 2025, up 12.65% from a year ago — trailing twelve months through Dec 2025 was $2.6 million (up 9.02% YoY), and the annual figure for FY2025 was $2.6 million, up 9.02%.
  • Amortization - Intangibles for Q4 2025 was $677000.0 at Sarepta Therapeutics, roughly flat from $677000.0 in the prior quarter.
  • Over the last five years, Amortization - Intangibles for SRPT hit a ceiling of $763000.0 in Q4 2023 and a floor of $170000.0 in Q1 2021.
  • Median Amortization - Intangibles over the past 5 years was $309000.0 (2021), compared with a mean of $400300.0.
  • Biggest five-year swings in Amortization - Intangibles: surged 326.26% in 2023 and later decreased 21.23% in 2024.
  • Sarepta Therapeutics' Amortization - Intangibles stood at $179000.0 in 2021, then changed by 0.0% to $179000.0 in 2022, then soared by 326.26% to $763000.0 in 2023, then decreased by 21.23% to $601000.0 in 2024, then increased by 12.65% to $677000.0 in 2025.
  • The last three reported values for Amortization - Intangibles were $677000.0 (Q4 2025), $677000.0 (Q3 2025), and $667000.0 (Q2 2025) per Business Quant data.